Agios to Present at Morgan Stanley Global Healthcare Conference Tuesday, September 13, 2016
September 06, 2016 08:05 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
Agios Appoints Andrew Hirsch as Chief Financial Officer
August 16, 2016 07:30 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
Agios to Present at Canaccord Genuity 36th Annual Growth Conference Wednesday, August 10, 2016
August 05, 2016 07:01 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., Aug. 05, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
Agios Reports Second Quarter 2016 Financial Results
August 04, 2016 07:01 ET
|
Agios Pharmaceuticals
- Data from PKR Activators at EHA Demonstrated Proof-of-Concept for AG-348 and Proof-of-Mechanism for AG-519; Program Moving Toward Pivotal Development in PK Deficiency with Molecule Selection by...
Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
July 28, 2016 16:01 ET
|
Agios Pharmaceuticals
CAMBRIDGE, Mass., July 28, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced...
AG-348 Achieves Proof-of-Concept in Ongoing Phase 2 DRIVE-PK Study and Demonstrates Rapid and Sustained Hemoglobin Increases in Adults with Pyruvate Kinase Deficiency
June 11, 2016 08:00 ET
|
Agios Pharmaceuticals
- 9 of 18 Total Patients and 9 of 13 Patients with at Least One Missense Mutation Showed Maximal Hemoglobin Increases Between 2.3 to 4.9 g/dL - - AG-348 Well Tolerated with...
Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
June 09, 2016 09:21 ET
|
Agios Pharmaceuticals
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing - - Robust Dose-Dependent Changes in ATP and 2,3-DPG Blood Levels Observed Consistent with PKR Enzyme Activation...
Agios to Host Conference Call from the 21st Congress of the European Hematology Association
June 01, 2016 07:01 ET
|
Agios Pharmaceuticals, Inc.
CAMBRIDGE, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that...
Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
May 19, 2016 07:01 ET
|
Agios Pharmaceuticals, Inc.
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study Company to Host Conference Call and Webcast on Saturday, June 11,...
Agios Updates 2016 Financial Guidance
May 17, 2016 16:02 ET
|
Agios Pharmaceuticals, Inc.
- $200 Million Upfront Payment from Celgene for New Metabolic Immuno-Oncology Collaboration - - Agios Expects 2016 Ending Cash Position of More than $390 Million - - Investor Conference Call...